NR0B1 and atherosclerosis: Appealing therapeutic targets for reducing hypercholesterolemia and atherosclerosis include members of the nuclear hormone receptor superfamily, such as the peroxisome proliferator–activated receptor and the liver X receptor subfamilies, among others.